[go: up one dir, main page]

GB201210328D0 - Biomarker - Google Patents

Biomarker

Info

Publication number
GB201210328D0
GB201210328D0 GB201210328A GB201210328A GB201210328D0 GB 201210328 D0 GB201210328 D0 GB 201210328D0 GB 201210328 A GB201210328 A GB 201210328A GB 201210328 A GB201210328 A GB 201210328A GB 201210328 D0 GB201210328 D0 GB 201210328D0
Authority
GB
United Kingdom
Prior art keywords
patient
methods
relates
tnf
symptoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GB201210328A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford University Innovation Ltd
Original Assignee
Oxford University Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford University Innovation Ltd filed Critical Oxford University Innovation Ltd
Priority to GB201210328A priority Critical patent/GB201210328D0/en
Publication of GB201210328D0 publication Critical patent/GB201210328D0/en
Priority to PCT/GB2013/051518 priority patent/WO2013186541A1/en
Ceased legal-status Critical Current

Links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Chemistry (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention relates to methods of determining whether or not a patient is suitable for anti-tumour necrosis factor (anti-TNF) therapy. The invention also relates to methods of treating autoimmune diseases and methods of identifying whether or not a patient is at risk of developing multiple sclerosis (MS) or MS-like symptoms or whether or not a patient has MS. The invention further provides novel polypeptide TNF antagonists and related polynucleotides, expression vectors, host cells and antibodies.
GB201210328A 2012-06-12 2012-06-12 Biomarker Ceased GB201210328D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GB201210328A GB201210328D0 (en) 2012-06-12 2012-06-12 Biomarker
PCT/GB2013/051518 WO2013186541A1 (en) 2012-06-12 2013-06-10 Biomarker for determining the suitability of anti -tumour necrosis factor (anti-tnf) therapy in the treatment of autoimmune diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB201210328A GB201210328D0 (en) 2012-06-12 2012-06-12 Biomarker

Publications (1)

Publication Number Publication Date
GB201210328D0 true GB201210328D0 (en) 2012-07-25

Family

ID=46605772

Family Applications (1)

Application Number Title Priority Date Filing Date
GB201210328A Ceased GB201210328D0 (en) 2012-06-12 2012-06-12 Biomarker

Country Status (2)

Country Link
GB (1) GB201210328D0 (en)
WO (1) WO2013186541A1 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7939634B2 (en) * 2004-01-27 2011-05-10 Compugen Ltd. Polynucleotides encoding polypeptides and methods using same
US7785834B2 (en) * 2005-11-10 2010-08-31 Ercole Biotech, Inc. Soluble TNF receptors and their use in treatment of disease
EP2069533B1 (en) * 2006-07-13 2012-11-07 Life Technologies Corporation Gene expression profiling for identification, monitoring and treatment of multiple sclerosis
WO2008093323A2 (en) * 2007-01-29 2008-08-07 Compugen Ltd. Novel nucleotide and amino acid sequences, and methods of use thereof for diagnosis

Also Published As

Publication number Publication date
WO2013186541A1 (en) 2013-12-19

Similar Documents

Publication Publication Date Title
ZA202409972B (en) Fcrn antagonists and methods of use
MX2013012167A (en) Bcma-based stratification and therapy for multiple myeloma patients.
MX2022006075A (en) Therapeutic and diagnostic methods for cancer.
PH12019501241A1 (en) Novel t cell receptors and immune therapy using the same
EA201692192A1 (en) Fcrn Anti-Body Binding for the Treatment of Autoimmune Diseases
WO2012106556A3 (en) Methods and compositons relating to inhibition of igf-1r
EA201391789A1 (en) TNF-ALPHA ANTIGENS-BINDING PROTEINS OWNED BY INCREASED FcRn BINDING
MX2015016814A (en) Anti-tweakr antibodies and uses thereof.
MX2019014695A (en) Interleukin-2 fusion proteins and uses thereof.
MY205262A (en) Novel t cell receptors and immune therapy using the same
EA201270713A1 (en) PROTEINS BASED ON FIBRONECTIN WITH FRAMED DOMAINS THAT BIND IL-23
MX362591B (en) Methods of treating rheumatoid arthritis using il-17 antagonists.
PH12017500331A1 (en) Antigen binding proteins that bind cxcr5
MY156353A (en) Methods of treating autoimmune diseases with dll4 antagonists
CL2012002081A1 (en) Humanized antibody that binds to the human il-7 receptor alpha chain (cd127); antigen binding protein comprising one or more complementarity determining regions of said antibody; nucleic acid molecule encoding an antibody or enhancement protein; expression vector, recombinant host cell; procedure for the production of an antigen binding protein; procedure to treat autoimmune or inflammatory disease.
GB201021289D0 (en) Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer
MX2011012039A (en) Blocking anti-dkk-1 antibodies and their uses.
MX347972B (en) Stable and soluble antibodies inhibiting vegf.
WO2011154139A3 (en) Gene expression markers for predicting response to interleukin-6 receptor-inhibiting monoclonal antibody drug treatment
EA201690503A1 (en) ANTIBODIES
MX2020010094A (en) Kir3dl3 as an hhla2 receptor, anti-hhla2 antibodies, and uses thereof.
MX2017004742A (en) Methods for prediction of anti-tnf alpha drug levels and autoantibody formation.
EA201400964A1 (en) CX3CR1-BONDING POLYPEPTIDES
HK1208236A1 (en) Antigen binding proteins that bind ccr2
EA201591796A1 (en) ANTIBODIES TO CD52

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)